{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T12:14:06Z","timestamp":1753272846328,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012330","name":"Okayama University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although chimeric antigen receptor T-cell (CAR-T) therapies have dramatically improved the outcomes of relapsed\/refractory B-cell malignancies, recipients suffer from severe humoral immunodeficiencies. Furthermore, patients with coronavirus disease 2019 (COVID-19) have a poor prognosis, as noted in several case reports of recipients who had COVID-19 before the infusion. We report the case of a 70-year-old woman who developed COVID-19 immediately before CAR-T therapy for high-grade B-cell lymphoma. She received Tixagevimab\u2212Cilgavimab chemotherapy and radiation therapy but never achieved remission. She was transferred to our hospital for CAR-T therapy, but developed COVID-19. Her symptoms were mild and she was treated with long-term molnupiravir. On day 28 post-infection, lymphodepleting chemotherapy was restarted after a negative polymerase chain reaction (PCR) test was confirmed. The patient did not experience recurrence of COVID-19 symptoms or severe cytokine release syndrome. Based on the analysis and comparison of the previous reports with this case, we believe that CAR-T therapy should be postponed until a negative PCR test is confirmed. In addition, Tixagevimab\u2212Cilgavimab and long term direct-acting antiviral agent treatment can be effective prophylaxis for severe COVID-19 and shortening the duration of infection.<\/jats:p>","DOI":"10.1007\/s12185-024-03711-5","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T08:01:55Z","timestamp":1707811315000},"page":"459-464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma"],"prefix":"10.1007","volume":"119","author":[{"given":"Kenta","family":"Hayashino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3484-0265","authenticated-orcid":false,"given":"Keisuke","family":"Seike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaho","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisato","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Terao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Kamoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Asada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisakazu","family":"Nishimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ennishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuharu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"issue":"10","key":"3711_CR1","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ajh.26301","volume":"96","author":"JR Westin","year":"2021","unstructured":"Westin JR, Kersten MJ, Salles G, Abramson JS, Schuster SJ, Locke FL, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021;96(10):1295\u2013312.","journal-title":"Am J Hematol"},{"issue":"12","key":"3711_CR2","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1038\/s41375-021-01466-0","volume":"35","author":"AM Spanjaart","year":"2021","unstructured":"Spanjaart AM, Ljungman P, de La Camara R, Tridello G, Ortiz-Maldonado V, Urbano-Ispizua A, et al. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the european society for blood and marrow transplantation (EBMT) infectious diseases working party and the european hematology association (EHA) lymphoma group. Leukemia. 2021;35(12):3585\u20138.","journal-title":"Leukemia"},{"issue":"4","key":"3711_CR3","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/cam4.4519","volume":"11","author":"Z Mohseni Afshar","year":"2022","unstructured":"Mohseni Afshar Z, Hosseinzadeh R, Barary M, Ebrahimpour S, Alijanpour A, Sayad B, et al. Challenges posed by COVID-19 in cancer patients: a narrative review. Cancer Med. 2022;11(4):1119\u2013235.","journal-title":"Cancer Med"},{"issue":"3","key":"3711_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.20892\/j.issn.2095-3941.2020.0289","volume":"17","author":"C Liu","year":"2020","unstructured":"Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med. 2020;17(3):519\u201327.","journal-title":"Cancer Biol Med"},{"issue":"3","key":"3711_CR5","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.cmi.2022.10.030","volume":"29","author":"D Luque-Paz","year":"2023","unstructured":"Luque-Paz D, Sesques P, Wallet F, Bachy E, Ader F. B-cell malignancies and COVID-19: a narrative review. Clin Microbiol Infect. 2023;29(3):332\u20137.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"3711_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/hon.3086","volume":"41","author":"F Passamonti","year":"2023","unstructured":"Passamonti F, Nicastri E, Di Rocco A, Guarini A, Ibatici A, Luminari S, et al. Management of patients with lymphoma and COVID-19: Narrative review and evidence-based practical recommendations. Hematol Oncol. 2023;41(1):3\u201315.","journal-title":"Hematol Oncol"},{"issue":"2","key":"3711_CR7","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/blood.2022018283","volume":"141","author":"JA Davis","year":"2023","unstructured":"Davis JA, Granger K, Roubal K, Smith D, Gaffney KJ, McGann M, et al. Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies. Blood. 2023;141(2):200\u20133.","journal-title":"Blood"},{"issue":"8","key":"3711_CR8","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","volume":"8","author":"K Maneikis","year":"2021","unstructured":"Maneikis K, \u0160ablauskas K, Ringelevi\u010di\u016bt\u0117 U, Vaitek\u0117nait\u0117 V, \u010cekauskien\u0117 R, Kry\u017eauskait\u0117 L, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in lithuania: a national prospective cohort study. Lancet Haematol. 2021;8(8):e583\u201392.","journal-title":"Lancet Haematol"},{"issue":"13","key":"3711_CR9","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1200\/JCO.21.02419","volume":"40","author":"Q Song","year":"2022","unstructured":"Song Q, Bates B, Shao YR, Hsu FC, Liu F, Madhira V, et al. Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the national COVID Cohort collaborative. J Clin Oncol. 2022;40(13):1414\u201327.","journal-title":"J Clin Oncol"},{"key":"3711_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.706431","volume":"11","author":"V Nilius-Eliliwi","year":"2021","unstructured":"Nilius-Eliliwi V, Mika T, Baraniskin A, W\u00fcnnenberg M, Maslova M, Boy C, et al. Successful chimeric antigen receptor (CAR) T-Cell treatment in aggressive lymphoma despite coronavirus disease 2019 (CoVID-19) and prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication - case report. Front Oncol. 2021;11: 706431.","journal-title":"Front Oncol"},{"issue":"1","key":"3711_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00277-022-05029-w","volume":"102","author":"N Buchtele","year":"2023","unstructured":"Buchtele N, Wohlfarth P, Staudinger T, Schellongowski P, Traby L, Vossen M, et al. CD19 CAR T-cell infusion during severe COVID-19 acute respiratory distress syndrome in large B-cell lymphoma. Ann Hematol. 2023;102(1):231\u20134.","journal-title":"Ann Hematol"},{"key":"3711_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13256-020-02598-0","volume":"15","author":"D Madduri","year":"2021","unstructured":"Madduri D, Parekh S, Campbell TB, Neumann F, Petrocca F, Jagannath S. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report. J Med Case Rep. 2021;15:90.","journal-title":"J Med Case Rep"},{"issue":"11","key":"3711_CR13","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1038\/s41409-020-0919-0","volume":"55","author":"P Ljungman","year":"2020","unstructured":"Ljungman P, Mikulska M, de la Camara R, Basak GW, Chabannon C, Corbacioglu S, et al. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplant. 2020;55(11):2071\u20136.","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"3711_CR14","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/cid\/ciaa351","volume":"71","author":"K Xu","year":"2020","unstructured":"Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W, et al. Factors Associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2020;71(15):799\u2013806.","journal-title":"Clin Infect Dis"},{"key":"3711_CR15","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1056\/NEJMc2031670","volume":"383","author":"T Aydillo","year":"2020","unstructured":"Aydillo T, Gonzalez-Reiche AS, Aslam S, van de Guchte A, Khan Z, Obla A, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. New Engl J Med. 2020;383:2586\u20138.","journal-title":"New Engl J Med"},{"key":"3711_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2147\/IDR.S396271","volume":"16","author":"A Onishi","year":"2023","unstructured":"Onishi A, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Fujino T, Miyashita A, et al. Impact of treatment with anti-CD20 monoclonal antibody on the production of neutralizing antibody against anti\u2013SARS-CoV-2 vaccination in mature B-Cell neoplasms. Infect Drug Resist. 2023;16:509\u201319.","journal-title":"Infect Drug Resist"},{"key":"3711_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105581","volume":"213","author":"S Dichtl","year":"2023","unstructured":"Dichtl S, Diem G, J\u00e4ger M, Zaderer V, Lupoli G, D\u00e4chert C, et al. Antiviral drugs block replication of highly immune-evasive omicron subvariants ex vivo, but fail to reduce tissue inflammation. Antiviral Res. 2023;213: 105581.","journal-title":"Antiviral Res"},{"key":"3711_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-022-01959-9","author":"MG Johnson","year":"2023","unstructured":"Johnson MG, Strizki JM, Brown ML, Wan H, Shamsuddin HH, Ramgopal M, Florescu DF, et al. Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial. Infection. 2023. https:\/\/doi.org\/10.1007\/s15010-022-01959-9.","journal-title":"Infection"},{"key":"3711_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ijid.2020.12.050","volume":"104","author":"D Camprub\u00ed","year":"2021","unstructured":"Camprub\u00ed D, Gaya A, Marcos MA, Mart\u00ed-Soler H, Soriano A, Mosquera MDM, et al. Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir. Int J Infect Dis. 2021;104:379\u201381.","journal-title":"Int J Infect Dis"},{"issue":"5","key":"3711_CR20","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s12185-022-03518-2","volume":"117","author":"S Ambati","year":"2023","unstructured":"Ambati S, Ali B, Seddon O, Godkin A, Scurr M, Moore C, Rowntree C, et al. Resolution of persistent SARS-CoV-2 infection with prolonged intravenous remdesivir and vaccination in a patient post CAR-T. Int J Hematol. 2023;117(5):765\u20138.","journal-title":"Int J Hematol"},{"key":"3711_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ijid.2023.04.412","volume":"133","author":"D Marangoni","year":"2023","unstructured":"Marangoni D, Antonello RM, Coppi M, Palazzo M, Nassi L, Streva N, et al. Combination regimen of nirmatrelvir\/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature. Int J Infect Dis. 2023;133:53\u20136.","journal-title":"Int J Infect Dis"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03711-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03711-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03711-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T13:14:54Z","timestamp":1711199694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03711-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,13]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["3711"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03711-5","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2024,2,13]]},"assertion":[{"value":"29 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in the study were in accordance with the ethical standards of the institutional and\/or national research committee and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}